Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model  Seyit Temel Ceyhan, Onder Onguru, Ulas Fidan, Tayfun Ide, Halil Yaman, Selim Kilic, Iskender Baser  European Journal of Obstetrics and Gynecology and Reproductive Biology  Volume 154, Issue 1, Pages 100-104 (January 2011) DOI: 10.1016/j.ejogrb.2010.09.003 Copyright © 2010 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 The size of endometriotic implants regressed significantly in letrozole, etanercept and infliximab treated groups. The figure shows an implant on the peritoneal surface of the abdominal wall in letrozole treated group before treatment (A) and its regression in the same group after a 21-day treatment (B). European Journal of Obstetrics and Gynecology and Reproductive Biology 2011 154, 100-104DOI: (10.1016/j.ejogrb.2010.09.003) Copyright © 2010 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Immunohistochemical examination of a sample from an animal in letrozole treated group with marked VEGF immunoreactivity in both glandular epithelial and stromal cells before treatment (A). VEGF immunoreactivity after letrozole treatment (B) was significantly weaker than before treatment. However, in the infliximab treated group, no significant difference was observed between pre- (C) and post-treatment (D). European Journal of Obstetrics and Gynecology and Reproductive Biology 2011 154, 100-104DOI: (10.1016/j.ejogrb.2010.09.003) Copyright © 2010 Elsevier Ireland Ltd Terms and Conditions